Takeda gets FDA labeling approvals for Actoplus Met and Kazano
Both diabetes combination pills received approved supplemental labeling submissions from the FDA, with new labels dated August 18, 2026.
Takeda closed out two routine labeling supplements this week for its type 2 diabetes combination tablets.
- Actoplus Met (metformin hydrochloride/pioglitazone hydrochloride), an oral tablet from Takeda Pharms USA, had its labeling supplement 27 approved1, with the updated label posted on August 18, 2026 and the approval letter dated August 14, 2026.
- Kazano (alogliptin benzoate/metformin hydrochloride), also an oral tablet from Takeda Pharms USA, had its labeling supplement 19 approved2, with the new label likewise dated August 18, 2026 and the approval letter dated August 14, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.